Disc Medicine, Inc. - 10-Q Filing
Disc Medicine, Inc. reports Q3 financial results including ongoing research and development expenses for Bitopertin and Selcodebart programs.
Tickers: $IRON
Read the full article at SEC EDGAR
Part of the story Disc Medicine, Inc. - 8-K Filing (3 articles)